SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study

Dib, Martin; Le Corre, Nicole; Ortiz, Catalina; Garcia, Daniel; Ferres, Marcela; Martinez-Valdebenito, Constanza; Ruiz-Tagle, Cinthya; Jose Ojeda, Maria; Espinoza, Manuel A.; Jara, Aquiles; Pablo Arab, Juan; Rabagliati, Ricardo; Vizcaya, Cecilia; Elena Ceballos, Maria; Sarmiento, Mauricio; et. al.


Background Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-gamma and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.

Más información

Título según WOS: ID WOS:000892490600010 Not found in local WOS DB
Volumen: 16
Editorial: Elsevier
Fecha de publicación: 2022


Notas: ISI